Recent studies have converged on the intersection of GLP-1|GIP|GCGR stimulant therapies and dopaminergic neurotransmission. While GLP activators are increasingly employed for managing type 2 diabetes mellitus, their unexpected effects on reinforcement circuits, specifically mediated by DA systems, are receiving significant attention. This paper … Read More